Archive for November 2020

ICER has long sought data generated outside clinical trials to enhance the understanding of how medical treatments perform in the real world Only 15% of clinical trials included could be feasibly replicated using currently available real-world data sources “Aetion’s rapid-cycle analytics will enable us to quickly generate evidence with the needed rigor and transparency to include…

An article we posted earlier this year stated that the RWE market was set to grow to being worth over $1 billion by 2023. However, now new research shows the market will grow massively in the 4 years following to being worth over $5 billion by 2027. It’s very possible that real-world evidence studies have…

Patients EPRs were utilised to generate RWE on treatment patterns and clinical outcomes for patients with aNSCLC in the UK 1003 patients who started a first-line treatment for aNSCLC were included from nine UK hospitals The evidence highlighted the need for improved treatment options for tumours lacking targetable mutations Click here to read more About SVMPharma SVMPharma is an…

The partner companies will evaluate the ability of the drugs to reduce or mitigate the severity of acute respiratory distress syndrome (ARDS), which is observed in around 10-15% of COVID-19 patients As part of the alliance, members are sharing clinical trial data and RWE, as well as crowd-sourcing early-stage candidates to identify mechanisms or treatments…

Yescarta is the first CAR-T therapy approved by the FDA in the treatment of large B-cell lymphoma The Center for International Blood and Marrow Transplant Research and Kite study has reached it’s enrolment target of 1,500 patients 2 years early The FDA has required this long-term study for Yescarta which will follow the participants for…